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Which five molecules would you take to a remote island? If you imagine yourself as a castaway on an island
youmight pickwater, glucose, penicillin, and ethanol in combinationwith aspirin. However, as a scientist, you
may ask yourself which molecules impressed you most by their chemical or biological property, their impact
on science, or the ingenuity and/or serendipity behind their discovery. Here, we present our personal short
list comprising FK506, colchicine, imatinib, Quimi-Hib, and cidofovir. Obviously, our selection is highly
subjective and, therefore, we apologize up front to our colleagues for not mentioning their favorite
compounds.FK506
FK506 is a fascinating molecule because
of both its medical impact and its
intriguing mode of action. FK506 is a mac-
rolide with immunosuppressant activity
produced by the bacterium Streptomyces
tsukubaensis, giving FK506 the alternative
name Tacrolimus (Tsukuba macrolide
immunosuppressant). FK506 was identi-
fied in 1984 in the course of a systematic
search for novel immunosuppressant
agents by a Japanese team headed by
T. Goto, T. Kino, and H. Hatanaka (Goto
et al., 1987; Tanaka et al., 1987). Ten
years later, FK506 was already approved
for use in liver transplantation, and by
now is a widely applied suppressor of
allograft rejections. Its medical impor-
tance fueled the search for the cellular
target of FK506 and succeeded in the
identification of FKBP (FK506-binding
protein), a peptidyl-prolyl isomerase
(PPIase) (Harding et al., 1989; Siekierka
et al., 1989, 1990; Standaert et al., 1990).
PPIases increase the rate of protein
folding by catalyzing the cis–trans isomer-
isation of peptide bonds N-terminal to
proline residues. FK506 inhibits FKBP
by a substrate mimicking mechanism,
whereby the a-keto amide of FK506
serves as a surrogate for the twisted
amide of a bound peptide substrate
(Rosen et al., 1990). However, the loss of
PPIase activity is not the basis of the
T cell inhibition by FK506. Instead, the
complex of FK506 and FKBP inhibits
the phosphatase calcineurin (CaN), also
known as PP2B, thereby preventing the
dephosphorylation of NF-AT (nuclear
factor of activated T cells) that is required
for the expression of early T cell activation556 Chemistry & Biology 17, June 25, 2010 ªgenes, e.g. IL-2 (Liu et al., 1991). Neither
FK506 nor its target FKBP by itself can
bind to CaN. Thus, rather than by simply
inhibiting the function of its target pro-
tein, FK506 induces a gain-of-function
by imparting new binding properties to
FKBP, which results in the termination
of the T cell receptor-initiated immune
response at the level of CaN (Figure 1).
For those not yet convinced by FK506’s
claim to be taken to a remote island,
it might be noteworthy that the story
of immunosuppressants is even more
complicated because the small molecules
cyclosporine A (CsA) and rapamycin
suppress T cell activation by a related,
yetdistinct pathway (for review, see Powell
and Zheng [2006]). CsA, a cyclic undeca-
peptide produced by the fungusBeauveria
nivea, binds to cyclophilin (CpN), a PPIase
unrelated in sequence to FKBP. However,
both the complexes FK506/FKBP and
CsA/CpN converge on calcineurin and
thus suppress T cell activation by a
common mechanism, i.e., inhibiting the
dephosphorylation of NF-AT by CaN. On
the contrary, rapamycin, a macrolide
chemically related to FK506 and produced
by the bacterium Streptomyces sirolimus,
binds to FKBP-like FK506, but the FKBP/
rapamycin complex interacts with mam-
malian target of rapamycin (mTOR), a
serine-threonine protein kinase, instead
of CaN and exerts its immunosuppressive
activity by inhibiting the response to IL-2
rather than its expression. Thus, FK506
and rapamycin share a common structural
element mediating binding to FKBP while
having different effector elements, result-
ing in the inhibition of different signaling
pathways (Bierer et al., 1990).2010 Elsevier Ltd All rights reservedFK506’s mode of inhibition is not only
intriguing and holds several unexpected
twists, but it is also an excellent example
of how the combined effort of chemists,
biologists, and physicians yielded a highly
potent small molecule that is not only
invaluable for basic research but also
indispensable for modern medicine.
Colchicine
The story of colchicine started in ancient
times, when Jason and his famous Argo-
nauts were sent to Colchis, the old
kingdom of Georgia, in Asia to retrieve
the Golden Fleece, which—according to
historians—was nothing but a mass of
golden crocus. In Europe, extracts of the
golden crocus was in great demand to
treat gout, which Hippocrates coined
podagra (podos = foot; agra = seizure)
due to the fact the first inflammations typi-
cally attack the foot. Two millennia later,
we now know that the active ingredient
of the mystic Asian pharmacophore is
colchicine, whose value as an anti-inflam-
matory agent for the treatment of gout is
still acknowledged (Figure 2). While the
isolation of the alkaloid colchicine from
Colchicum autumnale (Autumn crocus
also known as ‘‘Meadow saffron’’) was
first achieved by Pelletier and Caventou
in 1820 (Pelletier and Caventou, 1820),
its structure was not determined until
1940 (Cohen et al., 1940). Notably, the
cytological effect of colchicine was
already described in 1889 by Biaggio Per-
nice, a physician from Palermo (Pernice
and Caventou, 1889). He noted ‘‘quasi
tutti gli elementi in cariocinesi,’’ i.e., a
dramatic accumulation of mitotic cells
in the gastric and intestinal mucosa of
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Figure 1. Simplified Diagram of T Cell Receptor Mediated Signal
Transduction Pathway Resulting in the Expression of Interleukin 2
Receptor activation triggers a transient rise in intracellular calcium levels, and
thus the activation of the phosphatase calcineurin (CaN). Dephosphorylated
NF-AT enters the nucleus and induces the expression of IL2. Note that
FK506 and rapamycin share common structural elements mediating binding
to FKB, yet have distinct effector elements. FK506 binding protein, FKBP;
cyclophilin, CpN; mammalian target of rapamycin, mTOR.
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of colchicine. Subsequent
studies revealed that colchi-
cine had major effects on the
mitotic spindle (Dustin, 1934;
Eigsti, 1938; Levine, 1945)
and it was in fact colchicine’s
antimitotic effect that was
used to unambiguously deter-
mine that 46 is the normal
human diploid number of
chromosomes rather than
the previously believed 48
(Tjio and Levan, 1956). Thus,
colchicine has a one-of-a-
kind historical record as a
drug and a biological probe—
even before its target was
known. The advent of radio-
isotopes finally enabled
Edwin Taylor and Gary Borisy
to identify tubulin as the
cellular target of colchicine.
Colchicine-3H, prepared by
methylation of colchiceine
with diazomethane in tritiated
water, was found in a nonco-
valent complex with a macro-
molecule that showed acorre-
lation with the presence of
microtubules (Borisy and Tay-lor, 1967a, 1967b; Taylor, 1965). Using
colchicine-3H and GTP-3H, Taylor and
colleagues not only identified a 120kDa
dimer (i.e., the a-/b-tubulin-dimer) as the
target of colchicine, but also discovered
that only one of the two GTP molecules
bound per dimer is exchanged (Mohri,
1968; Shelanski and Taylor, 1967; Wei-
senberg et al., 1968). Today, we know
that the cycle of GTP hydrolysis and nucle-
otide exchange by b-tubulin forms the
basis for the key characteristic of microtu-
bules: dynamic instability. This phenom-
enon describes the stochastic bidirec-
tional switches of microtubules between
phases of growth and shrinkage that
allows them to quickly explore cellular
space, to direct cell movement, and
to segregate chromosomes (Desai and
Mitchison, 1997).
Does the identification of tubulin finally
disclose all mystery of colchicine? Not
really. It is still an open question of how
colchicine’s mode of action explains its
major clinical use in gout. Gout is caused
by the deposition of uric acid crystals in
joints and surrounding tissues. Colchicine
might prevent the formation of uric acidcrystals by modulating the pH of the tissue,
act as an anti-inflammatory agent by sup-
pressing the activity of neutrophils, or
inhibit the invasion of immune cells into
damage tissue—to name a few potential
explanations. Unlike other microtubule-
binding drugs, colchicine is not used in
cancer chemotherapy, probably due to
its high toxicity (Jordan and Wilson, 2004).
However, colchicine is widely applied
in plant breeding to produce diploid
gametes resulting in plants with stronger
flower colors. The binding of colchicine to
tubulin has several intriguing features. It is
a two-step process that includes a fast
reaction yielding a low-affinity complex
followed by a slow, unimolecular step to
form the poorly reversible colchicine-
tubulin (TC) complex (Engelborghs, 1998).
The TC complex incorporates at the end of
growing microtubules where it prevents
curved tubulin from adopting a straight
conformation. This conformational con-
straint prevents the stabilization of lateral
contacts between tubulin subunits result-
ing in loss of dynamic instability and the
depolymerization of microtubules at low
and at high TC concentrations, respec-Chemistry & Biology 17, June 25, 2010 ª2010 Elsetively (Panda,etal., 1995,Rav-
elli, et al., 2004). Colchicine
binds to a single site on b-
tubulin (colchicine site), which
is shared by a large number of
molecules structurally unre-
lated to colchicine, e.g., podo-
phyllotoxin, combrestatin-A4.
The high specificity of colchi-
cine for tubulin fueled the
search for an endogenous
molecule that regulates micro-
tubule dynamics via the col-
chicine site. However, identi-
fied candidates have not
been widely accepted. Thus,
the story of colchicine has still
to be continued.
4-[(4-Methylpiperazin-1-
yl)methyl]- N-[4-methyl-
3-[(4-pyridin-3-
ylpyrimidin-2-yl)amino]
phenyl]benzamid
This is better known as glee-
vec, glivec, imatinib, STI571,
or the magic bullet for the
treatment of chronic myelog-
enous leukemia (CML) (Fig-
ure 3). CML is a malignancy of
a pluripotent hematopoieticstem cell. Ninety-five percent of CML
patients are positive for the Philadelphia
(Ph) chromosome, which was named after
the location of the two research insti-
tutes where it was first discovered and
described (Nowell, 1962; Rowley, 1973).
The Ph-chromosome is the result of
t(9;22)(q34;q11), i.e., the reciprocal trans-
location between the large arms of
chromosome 9 and 22. The molecular
consequence of this translocation is a
replacement of the first exon of the proto-
oncogene c-Abl with sequences from the
BCR (‘‘break point cluster region’’) (Heist-
erkamp et al., 1985; Konopka et al., 1984;
Shtivelman et al., 1985). c-Abl encodes
a nonreceptor tyrosine kinase that has
tightly controlled activity in normal cells.
In contrast, the protein product of the
Bcr-Abl fusion shows constitutive tyrosine
kinase activity. Thus, BCR-Abl allows cells
to proliferate in a cytokine-independent
manner. Furthermore, BCR-Abl’s inhibi-
tory effect on DNA repair induces genomic
instability, which might be causative for the
feared blast crisis in CML.
The story of imatinib began in the
early 1990s at Ciba-Geigy (now Novartis)vier Ltd All rights reserved 557
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Figure 2. Colchicine and Its Effect on Mitosis
(A) First description of colchicine’s effect on cells in mitosis by the Italian physician Biaggio Pernice, 1889
(image was obtained through the Biodiversity Heritage Library).
(B) Chemical structure of colchicine.
(C) Electron micrograph of sperm tail preparation showing the characteristic 9+2 microtubule structure,
i.e., two central microtubule doublets surrounded by nine outer doublets (Shelanski and Taylor, 1967).
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pyrimidine derivatives were screened for
inhibitory activity against protein tyrosine
kinases (PTKs). The originally identified
lead compound inhibited Abl-kinase
in vitro; however, its primary cellular target
was the platelet-derived growth factor
receptor (PDGF-R) PTK. Using this
compound as a lead structure, rational
drug design led to the identification of
imatinib, which inhibited the autophos-
phorylation of Abl and PDGF-R with equal
potency (Buchdunger et al., 1996). Impor-
tantly, colony formation assays with bone
marrow cultures from CML patients
demonstrated that imatinib inhibited the
growth of BCR-Abl positive cells to an
extent of 92%–98% (Druker et al., 1996).
Normal colonies were minimally affected,
despite the fact that imatinib inhibited
in vitro BCR-Abl and c-Abl with an
identical IC50. Extensive animal testing,
including a CML-mouse model, confirmed
imatinib’s high efficiency as well as low558 Chemistry & Biology 17, June 25, 2010 ªtoxicity and paved the way for the first clin-
ical trials just few years after its discovery.
Today, imatinib mesylate is approved as
first-line treatment for CML. Several
patients, however, develop drug resis-
tance partly due to amplification or muta-
tion of the BCR/ABL gene, suggesting
that combined therapies including imati-
nib should be considered (Waller, 2010).
Imatinib is an ATP-competitive inhib-
itor, raising the question of how this mole-
cule can be selective for the PTKs Abl,
PDGF-R, and c-kit, another PTK. The
crystal structure of Abl in complex with
an imatinib variant revealed that the inhib-
itor recognizes the inactive conformation
of the activation loop of Abl (Schindler
et al., 2000). For most kinases the activa-
tion loop controls catalytic activity. Impor-
tantly, the ‘‘active’’ conformation of the
loop, stabilized by phosphorylation, is
highly similar in all known structures of
active kinases, while the ‘‘inactive’’ con-
formation displays great diversity. Thus,2010 Elsevier Ltd All rights reserveddespite the highly conserved nucleotide-
binding pocket of kinases, the character-
istic conformation of the activation loop
in its inactive state allows imatinib to be
highly selective for its targets while being
essentially inactive against other PTKs
and serine/threonine kinases.
Why do we consider Imatinib worth
taking to a remote island? First, it is an
excellent example of the synergistic re-
search between academia and industry.
The combined efforts of Brian Druker,
Nicholas Lydon, and Charles Sawyers
were awarded with the Lasker-DeBakey
Award in 2009. Second, its intriguing
mode of action identified kinases as drug-
gable, despite the high sequence conser-
vation of their catalytic center. Third and
most importantly, it shifted the role of
physicians from checking blood counts
and delivering cruel news to efficiently
treating CML patients.
Quimi-Hib
Immunogens used in many vaccination
strategies derive from constituent parts
of the pathogen. For instance, the vaccine
against Haemophilus influenzae type
b (Hib), a pathogen that causes bacterial
meningitis and pneumonia that was intro-
duced around 1990 and reduced inci-
dences by more than 95%, is based on
a capsular polysaccharide isolated from
the pathogen. The usage of synthetic anti-
gens, and in particular carbohydrate
conjugates in which the immunogen is
synthesized chemically with atom scale
precision, holds great promise for further
developments along these lines (Astron-
omo and Burton, 2010). This is predomi-
nately due to the controlled production of
a homogenous compound that minimizes
batch-to-batch variability and thereby
increases quality control standards. This
might be accompanied with lower produc-
tion costs in comparison with conven-
tional vaccines. According to the World
Health Organization (http://www.who.int/
mediacentre/factsheets/fs294/en/index.
html), high costs are the cause for the
slow introduction of the Hib vaccination
in developing countries. A major leap
forward in this field represents the devel-
opment of the first synthetic conjugate
polysaccharide vaccine that was reported
2004 by a Cuban-Canadian research team
(Verez-Bencomo et al., 2004). They first
developed a high yielding route for the
synthesis of a Hib polysaccharide
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polyribosylribitol phosphate
(Figure 3). These oligomers
with an average of eight
repeating units were repro-
ducibly obtained in high yields
(80%). The antigen was con-
jugated to suitable carriers
and immunogenicity studies
performed in animals, adults,
children, and infants. After
several clinical trials, a 99.7%
success rate was obtained,
leading to commercial pro-
duction as a vaccine (Quimi-
Hib by Heber Biotech). This
makes the polyribosylribitol
phosphate conjugates to the
first successful synthetic
carbohydrate antigen. Given
the great potential of medic-
inal chemistry nowadays and,
in particular, carbohydratechemistry, the approach of using syn-
thetic antigens should allow the intro-
duction of artificial carbohydrate analogs
for increasing the immunogenicity of the
conjugates in future.
(S)-1-(3-Hydroxy-2-
phosphonylmethoxypropyl)
cytosine, Better Known as Cidofovir
Compared to the structures that we have
discussed before, cidofovir impresses by
its structural simplicity (Figure 3). Cidofo-
vir is an acyclic nucleoside phosphonate
with very broad antiviral activity. Acyclic
nucleosides may be described as nucleo-
side analogs with opened, simplified
sugar surrogates. How was it discovered?
The history of acylic nucleoside analogs
had its coming of age with the discovery
of acyclovir as a selective inhibitor of
herpes simplex virus (HSV) replication
(De Clercq, 2008). In order to gain antiviral
activity, nucleosides need to be phosphor-
ylated to the triphosphates by three
kinase-promoted steps. The resulting
triphosphate is then used predominantly
by the viral enzymes for incorporation of
the modified nucleotide in the nascent
DNA, and thus selectively impedes viral
replication. Interestingly, although acyclo-
vir is an acyclic guanosine analog, it was
found by Elion et al. (1977) that the viral
thymidine kinasemoreefficiently promotes
the first phosphorylation step compared
to the cellular enzymes. This makes
acyclovir selective for virus-infected cells.Further phosphorylation is promoted by
the cellular kinases, resulting in the
triphosphates that impede viral replica-
tion. In 1986, De Clercq, Holy´, and col-
leagues reported on the discovery of a
new class of broad-spectrum anti-DNA
virus agents: nucleoside phosphonates.
(S)-9-(3-Hydroxy-2-phosphonylmethoxy-
propyl)adenine (HPMPA) (Figure 3) is
active against all tested DNA viruses (pol-
yoma, papilloma, adeno, herpes, pox) (De
Clercq et al., 1986). Cidofovir is a closely
related cytosine derivative of HPMPA that
has been further developed clinically and
has a remarkable broad-spectrum anti-
viral activity. It has been shown to be effi-
cacious in the treatmentofmanyDNAvirus
infections, including that of acyclovir-
resistant HSV and varicella-zoster virus.
Interestingly, since cidofovir has shown
promising effects in animal models, it
was predicted to be effective in the
prophylaxis and therapy of smallpox in hu-
mans, a threat of bioterrorism. Thus,
cidofovir is the sole antiviral drug that
has been reserved and stockpiled for
possible use in the therapy and prophy-
laxis of smallpox and the complications
of smallpox vaccination (De Clercq and
Holy´, 2005).
Why are these phosphonates so effec-
tive? As depicted above, most nucleoside
antiviral reagents get phosphorylated by
host kinases in order to generate antiviral
activity. The resulting triphosphates are
selective substrates for the viral DNA poly-Chemistry & Biology 17, June 25, 2010 ª2010 Elsemerases and, after incorpora-
tion of the acyclic nucleotide,
further DNA synthesis is obvi-
ated, a mechanism termed
chain termination. In contrast
to other antiviral nucleoside
analogs, the phosphonates
do not need the first phos-
phorylation step promoted
by a kinase, which is often
a bottleneck and counteracts
the activity of the compounds.
Chemistry & Biology
invites your comments on
this topic. Please write to
the editors at chembiol@
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